Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Barrett's Esophagus - 315 - 3 Way Cross-Over

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: March 11, 2008
Last updated: January 24, 2011
Last verified: January 2011
This study looks the intragastric and intraesophageal pH in patients with documented Barrett's esophagus whilst taking esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.

Condition Intervention Phase
Barrett's Esophagus
Drug: Esomeprazole Magnesium
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multicenter, Double-blind, Three-way Crossover Intraesophageal and Intragastric pH Study of Three Esomeprazole Treatment Regimens in Documented Barrett's Esophagus Patients

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To compare the total percent time during the 24-hour monitoring period that gastric pH is above 4.0 at steady state in patients when taking: esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily. [ Time Frame: pH measured on Day 5 ]

Secondary Outcome Measures:
  • Compare total percent time distal esophageal pH is above 4.0 at steady state for each treatment period. [ Time Frame: pH measured ]

Estimated Enrollment: 50
Study Start Date: March 2002
Study Completion Date: April 2003
Primary Completion Date: April 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
40mg twice daily
Drug: Esomeprazole Magnesium
Other Name: Nexium
Experimental: 2
40mg three times daily
Drug: Esomeprazole Magnesium
Other Name: Nexium
Experimental: 3
20mg three times daily
Drug: Esomeprazole Magnesium
Other Name: Nexium


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have a previously established, biopsy-proven diagnosis of Barrett's esophagus with segment length greater than 3cm, with no dysplasia or adenocarcinoma within the previous 12 months

Exclusion Criteria:

  • A history of esophageal, gastric, or duodenal surgery, including anti-reflux surgery or endoscopic anti-reflux procedures, except for simple closure of a gastric or duodenal ulcer.
  • History of various gastrointestinal diseases - please see investigator for full list.
  • Evidence of any malignant disease in the last 5 years, except minor superficial skin disease.
  • Unstable diabetes mellitus. Stable on a controlled diet, oral agents or insulin are acceptable.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00637559

Sponsors and Collaborators
Study Director: Paula Fernstrom Nexium Global Product Director, AstraZeneca
  More Information

Responsible Party: Tore Lind, MD - Nexium Medical Science Director, Astra Zeneca Identifier: NCT00637559     History of Changes
Other Study ID Numbers: 315
Study First Received: March 11, 2008
Last Updated: January 24, 2011

Keywords provided by AstraZeneca:
Barrett's esophagus

Additional relevant MeSH terms:
Barrett Esophagus
Digestive System Abnormalities
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 22, 2017